Clinical Trial Update: Does N-Acetylcysteine Decrease Spontaneous Oxidation of Central Neural Dopamine in Parkinson's Disease? [Phase 1]

View source ↗

Summary

Phase 1 trial investigating whether N-Acetylcysteine reduces spontaneous oxidation of central nervous system dopamine in Parkinson's disease; study terminated w…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Parkinson Disease

Drugs mentioned

• N-acetylcysteine (N-acetylcysteine)

Snippet

Sponsor: National Institute of Neurological Disorders and Stroke (NINDS) | Conditions: Parkinson Disease, Cerebrospinal Fluid | Phase 1 | Status: TERMINATED | Results posted: 2021-05-19